Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Careplus Group BhdXKLS:0163 Debt-to-EBITDA is -15.45 as of Mar. 2026. The stock has 5 warning signs investors should review. Among 466 Medical Devices & Instruments companies, Careplus Group Bhd ranks worse than 214592.06% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Careplus Group Bhd's Debt-to-EBITDA or its related term are showing as below:
XKLS:0163'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -6.79 Med: 3.04 Max: 4.91
Current: -0.6
During the past 13 years, the highest Debt-to-EBITDA Ratio of Careplus Group Bhd was 4.91. The lowest was -6.79. And the median was 3.04.
XKLS:0163's Debt-to-EBITDA is ranked worse than 100% of 466
companies
in the Medical Devices & Instruments industry
Industry Median: 1.585
vs XKLS:0163: -0.60
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Careplus Group Bhd Debt-to-EBITDA Related Terms
Careplus Group Bhd Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Careplus Group Bhd's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:0163 vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Careplus Group Bhd's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Careplus Group Bhd Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Careplus Group Bhd's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Careplus Group Bhd's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Careplus Group Bhd (XKLS:0163) has a Debt-to-EBITDA of -15.45 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Careplus Group Bhd. According to the industry distribution chart, Careplus Group Bhd ranks #999999 out of 466 companies in the Medical Devices & Instruments industry.
Is Careplus Group Bhd's Debt-to-EBITDA too high?
Careplus Group Bhd's current Debt-to-EBITDA is -15.45. Based on the distribution chart, Careplus Group Bhd ranks #999999 out of 466 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Careplus Group Bhd's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Careplus Group Bhd ranks #999999 out of 466 companies for Debt-to-EBITDA. This places Careplus Group Bhd in the lower half of its industry. The industry median Debt-to-EBITDA is 1.59. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.59, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Careplus Group Bhd. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Careplus Group Bhd's current Debt-to-EBITDA is -15.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Careplus Group Bhd stock overvalued right now?
Based on GuruFocus' analysis, Careplus Group Bhd (XKLS:0163) is currently considered Modestly Undervalued. The stock's GF Value™ is RM0.09, compared to a current price of RM0.07 — trading 22.2% below its estimated fair value. The current Debt-to-EBITDA is -15.45. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Careplus Group Bhd (XKLS:0163), the current Debt-to-EBITDA is -15.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Careplus Group Bhd is involved in the manufacturing, processing, and trading of gloves. The company's product consists of Latex exam gloves, Latex surgical gloves, and Nitrile exam gloves. Its Latex exam gloves are used in medical examinations and procedures, diagnostic procedures by the dentist, laboratory practices, and food handling practices. The Nitrile exam gloves are generally used in laboratory practices and the automotive industry. Geographically, it derives maximum revenue from Malaysia and the rest from North America, South America, Other Asia Pacific regions, and other regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0163 has been successfully added to your 
